Abstract
FIU inventors developed a novel fluorescence-based technology for measuring base excision repair capacity in whole cell lysates. Currently, base excision repair is measured through monitoring decreases of DNA damage, which lacks accuracy. Additionally, current plasmid transfection-based assays are hinged by the limited amount of plasmids containing various types of DNA lesions and the inefficiency of introduction of plasmids into different mammalian cells limiting the use of this method at a high throughput scale. The cell transfection-based technology for measuring base excision repair also prevents its application in measuring DNA repair capacity in human tissue. The proposed technology is simple, fast, and can be used for high-throughput measurement of base excision repair capacity of cell lysates for cells obtained from human population studies and patient tissue, and allows for screenings of anti-cancer drugs and environmental toxicants that can inhibit base excision repair pathways for disease prevention. in multiple OSs, while also opening up avenues for future developments and enhancements.
Benefit
Easy to implement assay using 96- or 384-well plates with a fluorescence plate reader and a temperature controlSimplified and quick assay that can be easily preformed within an hourEliminates the need for amplification of DNA by real-time PCR or cell cultureEasily adaptable assay for multiple purposes and in a variety of human samples
Market Application
High throughput screening platform for inhibitors of DNA repair in the treatment of cancer, and for the identification of environmental toxicants that inhibit DNA repairDevelopment of commercial kit for measurement of DNA repair capacity in human populations for the identification of biomarker for disease prevention, cancer drug resistanceMonitoring of DNA repair at specific genes and genome sequences as a biomarker for personal medicine and precision medicine
Brochure
